{"title":"BRCA 1/2突变与子宫癌风险：系统回顾与荟萃分析。","authors":"Faezeh Zakerinasab, Qumars Behfar, Reza Parsaee, Reza Hossein Zadeh, Elaheh Foroughi, Amirhesam Amirbeik, Ghazalehsadat Ahmadi","doi":"10.1186/s12863-024-01189-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>In this study, we aim to investigate the association between BRCA1/2 mutation and uterine cancer incidence.</p><p><strong>Material and method: </strong>We systematically searched three databases including PubMed, Scopus, and Google Scholar up to August 2023; and reviewed 23 cohorts and cross-sectional studies to explore the association between BRCA1/2 mutations and uterine cancer incidence.</p><p><strong>Results: </strong>This systematic review comprised a total of 21 cohort studies and 2 cross-sectional studies after the screening process. According to meta-analysis the prevalence of the BRCA1/2 gene in patients with uterine cancer was 0.02 (95%CI = [0.01,0.03], P < 0.01, I<sup>2</sup> = 94.82%) CONCLUSIONS: Our meta-analysis investigates a 2% prevalence of BRCA1/2 mutation in patients with uterine cancer. Patients with BRCA1/2 mutations might be more conscious of uterine malignancies.</p>","PeriodicalId":72427,"journal":{"name":"BMC genomic data","volume":"25 1","pages":"13"},"PeriodicalIF":1.9000,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10829221/pdf/","citationCount":"0","resultStr":"{\"title\":\"BRCA 1/2 mutations and risk of uterine cancer: a systematic review and meta-analysis.\",\"authors\":\"Faezeh Zakerinasab, Qumars Behfar, Reza Parsaee, Reza Hossein Zadeh, Elaheh Foroughi, Amirhesam Amirbeik, Ghazalehsadat Ahmadi\",\"doi\":\"10.1186/s12863-024-01189-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>In this study, we aim to investigate the association between BRCA1/2 mutation and uterine cancer incidence.</p><p><strong>Material and method: </strong>We systematically searched three databases including PubMed, Scopus, and Google Scholar up to August 2023; and reviewed 23 cohorts and cross-sectional studies to explore the association between BRCA1/2 mutations and uterine cancer incidence.</p><p><strong>Results: </strong>This systematic review comprised a total of 21 cohort studies and 2 cross-sectional studies after the screening process. According to meta-analysis the prevalence of the BRCA1/2 gene in patients with uterine cancer was 0.02 (95%CI = [0.01,0.03], P < 0.01, I<sup>2</sup> = 94.82%) CONCLUSIONS: Our meta-analysis investigates a 2% prevalence of BRCA1/2 mutation in patients with uterine cancer. Patients with BRCA1/2 mutations might be more conscious of uterine malignancies.</p>\",\"PeriodicalId\":72427,\"journal\":{\"name\":\"BMC genomic data\",\"volume\":\"25 1\",\"pages\":\"13\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-01-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10829221/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC genomic data\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s12863-024-01189-y\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC genomic data","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12863-024-01189-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
BRCA 1/2 mutations and risk of uterine cancer: a systematic review and meta-analysis.
Purpose: In this study, we aim to investigate the association between BRCA1/2 mutation and uterine cancer incidence.
Material and method: We systematically searched three databases including PubMed, Scopus, and Google Scholar up to August 2023; and reviewed 23 cohorts and cross-sectional studies to explore the association between BRCA1/2 mutations and uterine cancer incidence.
Results: This systematic review comprised a total of 21 cohort studies and 2 cross-sectional studies after the screening process. According to meta-analysis the prevalence of the BRCA1/2 gene in patients with uterine cancer was 0.02 (95%CI = [0.01,0.03], P < 0.01, I2 = 94.82%) CONCLUSIONS: Our meta-analysis investigates a 2% prevalence of BRCA1/2 mutation in patients with uterine cancer. Patients with BRCA1/2 mutations might be more conscious of uterine malignancies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
